SensiGen

David Kurnit, MD, PhD is co-founder of SensiGen and inventor of its technology. He serves as Chairman of the Scientific Advisory Board. Dr. Kurnit is a Professor of Pediatrics at the University of Michigan Medical Center and holds both a PhD in cell biology and an MD from Albert Einstein College of Medicine. He has received widespread support for his research including funding from the National Institutes of Health (National Institute of Child Health and Development and the National Cancer Institute) as well as the State of Michigan and private foundations. Dr. Kurnit has been a reviewer for key medical journals, including Cytogenetics and Cell Genetics, Nucleic Acids Research as well as for the National Institutes of Health. He has 115 original publications in peer reviewed scientific journals.

Michael D. Kane, PhD has extensive experience in scientific research, technology development, and business leadership. Dr. Kane holds a Ph.D. in Molecular Pharmacology from Purdue University. His professional background includes over 10 years experience in the pharmaceutical and biotechnology industry, specifically developing genomic technology, computational methods and pharmacological preclinical drug discovery research. Dr. Kane served as the Vice President of Research and Development for Genomics Solutions, Inc., a publicly traded scientific instrumentation and biotechnology company. His entrepreneurial experience includes founding a seed-stage biotechnology company capitalizing on his own patented scientific methods, procuring early stage capital investments, and leading his company as CEO. His patent portfolio includes innovations in biotechnology, molecular diagnostics, and wireless communications technology. Currently, Dr. Kane serves as a professor at Purdue University specializing in the development of bioinformatics tools, genomic detection technologies and high performance computing systems. Dr. Kane has over 30 peer reviewed publications, book chapters and technical publications. In addition, Dr. Kane serves as the Lead Genomic Scientist at Purdue University's Discovery Park, as well as the Director of Strategic Operations for a
seed-stage broadband telecommunications technology company.

Nicholas Alexander Kefalides, MD, PhD is currently Professor of Medicine-Emeritus and Professor of Biochemistry and Biophysics at the University of Pennsylvania. He received his M.D. degree and M.S. in Biochemistry in 1956. In 1965 he received Ph.D. in Biochemistry from the University of Illinois College Of Medicine in Chicago. Dr. Kefalides’ research focused on extracellular matrix and specifically on the kidney basement membrane. Dr. Kefalides' most recent work dealt with the discovery that a peptide sequence comprising residues 185-203 of the non-collagenous domain of the alpha 3 chain of Type IV collagen possesses unique functions, namely it inhibits the activation of neutrophils, inhibits the replication of tumor cells and the growth of tumors and inhibits angiogenesis in vivo and in vitro. He received the Borden Research Award in Medicine in 1956, a Guggenheim Foundation Fellowship in 1977, an Honorary Doctorate degree from the University of Reims in France in 1987 and an Award for Outstanding Research in Connective Tissues by the Gordon Research Conferences and The Collagen Corporation in 1997.

Mark H. Stoler, MD is Professor of Pathology and Clinical Obstetrics and Gynecology at the University of Virginia Health Sciences Center. He is an internationally recognized expert in Cytopathology, Gynecologic pathology and HPV biology. Dr. Stoler received his initial training in pathology, as well as his undergraduate and medical school training, at the University of Rochester. In 1993, Dr. Stoler was recruited to the University of Virginia where he is currently also the Associate Director of Surgical Pathology and Cytopathology.

Dr. Stoler is currently on the Board of Directors of the American Society for Clinical Pathology. He served on both the Steering Committee and Pathology Quality Control Committee for the NCI-sponsored ASCUS-LSIL Triage Study, a direct application of his research, which has focused on the study of gene expression in human disease, especially the relationship between human papillomaviruses and cervical carcinogenesis. He is editor-in-chief of both Diagnostic Molecular Pathology, and the International Journal of Gynecological Pathology and is an Associate Editor for the 4th Edition of Sternberg’s Diagnostic Surgical Pathology, the leading textbook of surgical pathology.